* Celgene submits new applications for blood cancer drugs
* Files for Revlimid as first-line treatment in Europe
* Files for Istodax in U.S. in peripheral T-cell lymphoma
BOSTON, Jan 4 (Reuters) - Biotechnology company Celgene Corp CELG.O said on Tuesday it has submitted new marketing applications for its blood cancer drugs Revlimid and Istodax.
The company submitted a marketing application in Europe to use Revlimid, in combination with the drugs melphalan and prednisone, in newly diagnosed patients with multiple myeloma. It also applied for the drug to be used as a maintenance therapy following initial treatment.
In addition, Celgene applied for European approval of Revlimid as a maintenance therapy for patients who have undergone a stem cell transplant.
The drug is currently approved in combination with dexamethasone for patients who have received, and failed to respond to, at least one prior therapy.
Celgene expects to file for approval of the drug in newly diagnosed patients in the United States later this year.
The company also filed for U.S. approval of Istodax for patients with peripheral T-cell lymphoma who have failed at least one prior therapy. The drug is already approved in the United States to treat cutaneous T-cell lymphoma in patients who failed at least one prior systemic therapy. (Reporting by Toni Clarke, editing by Dave Zimmerman)
Our Standards: The Thomson Reuters Trust Principles.